February 11, 1999
Dr Gro Harlem Brundtland
World Health Organization
Avenue Appia 20
CH-1211 GENEVA 27
Dear Director - General Brundtland:
This is an invitation to address a meeting on March 26, 1999 in Geneva that is being convened to discuss an initiative that seeks to improve access to AIDS and other essential medicines. In particular, the meeting will address the issue of compulsory licensing of patents on essential medical technologies. The meeting will last all day, and we would be grateful if you could make a presentation to the gathering in the morning, to open the event, or at any time that would be more convenient for you.
The meeting seeks to address aspects of the growing ethical and public health dilemmas associated with access to modern medical discoveries. As we witness new scientific advances in the treatment of disease, we are also confronted with highly disparate levels of access to treatments. Public health experts are concerned about the health consequence of national policies on the protection of intellectual property. Specifically, the meeting will be a dialogue over the appropriate use of national laws permitting compulsory licensing of patents for essential medical technologies.
As you know, although specifically allowed in international agreements on intellectual property, compulsory licensing of patents is a topic of some controversy. The purpose of this meeting is to begin a dialogue among stakeholders on several important factual, legal and ethical questions that will provide a context for policy making.
The specific agenda for the March 26 meeting has not yet been set. However, we expect to organize four panel discussions covering the following topics:
The meeting is being organized by Médecins Sans Frontières (MSF), Health Action International (HAI) and the Consumer Project on Technology (CPT). We recognize that not all participants in the meeting will share the views of the organizers, and there will be no effort to portray participation in the meeting as an endorsement of any particular view. Indeed, the meeting is intended to be a frank discussion of compulsory licensing, with a range of views expressed. We expect this dialogue to be constructive and important, and to educate participants about important factual and legal matters, and to deepen the participants' understanding of the role of compulsory licensing in our new rapidly changing global economy.
The participation of the World Health Organization is particularly useful and appropriate, given the WHO expertise and mission, and the recent recommendation by the Executive Board of the World Health Assembly regarding the Revised Drug Strategy.
The coordinator for this meeting is Catherine Gavin, who can be reached in the United States at 202.387.8030, fax 202.234.5176, by electronic mail at email@example.com, or by postal mail at P.O. Box 19367, Washington, DC 20036.
Bas Van der Heide
Health Action International
Tel +31.20.683.3684 Fax +31.20.685.5002, firstname.lastname@example.org
Dr. Bernard Pécoul
Médecins Sans Frontières
Tel +33(0)188.8.131.52.33, Fax +33(0)1 184.108.40.206, email@example.com
Consumer Project on Technology
Tel 202.387.8030, Fax 202.234.5176, firstname.lastname@example.org
PS: The Consumer Project on Technology has created a web site with background information on compulsory licensing at http://www.cptech.org/ip/health/cl